AMARIS MURRAY: Open Payments
NPI 1841844222 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,276 in 60 payments from 14 companies in 2025. Trend: 2023 $1,622 · 2024 $2,011 · 2025 $1,276
Food & beverage: $1,276
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $204 |
| Otsuka America Pharmaceutical, Inc. | 7 | $181 |
| Neurocrine BioSciences, Inc. | 5 | $138 |
| Alkermes, Inc. | 6 | $131 |
| Lundbeck LLC | 4 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $110 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 4 | $99 |
| E.R. Squibb & Sons, L.L.C. | 3 | $77 |
| Indivior Inc. | 1 | $35 |
Products named: VRAYLAR, INGREZZA, ABILIFY MAINTENA, REXULTI, ARISTADA, CAPLYTA, Auvelity, HETLIOZ.
Industry payments across MD — which companies pay providers there.
